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Abstract
This study examines the relationship between ecstasy use and suicidal behaviors among
adolescents in the United States. Data from the adolescent subsample (ages 12–17, N=19,301) of
the 2000 NHSDA were used in the analyses. Information on adolescent substance use, suicidal
behaviors and related socio-demographic, family and individual factors was obtained in the
survey. The rate of past year suicide attempt among adolescents with lifetime ecstasy use was
almost double that of adolescents who had used other drugs only, and nine times that of
adolescents with no history of illicit drug use. In multinomial logistic regression analyses,
controlling for related factors, the effect of ecstasy use remained significant. Adolescent ecstasy
users may require enhanced suicide prevention and intervention efforts.
1. INTRODUCTION
Suicide is the third leading cause of death for young people 10–24 years of age (CDC, 2010)
in the United States. Each year, approximately 149,000 youth between the ages of 10 and 24
receive medical care for self-inflicted injuries (CDC, 2007). Suicidality affects all youth, but
some subgroups are at a higher risk than others. Studies have shown that adolescents who
are substance abusers are more likely than others to attempt suicide (Borowsky et al., 2001;
Brent et al., 1993; Wu et al., 2004). Although abuse of alcohol, cocaine, and inhalants are
known to be risk factors for suicide attempt (Sakai et al., 2004; Vega et al., 2000; Wu et al.,
2004), little is known about the contribution of other specific drugs of abuse, such as
MDMA (3,4 methylenedioxymethamphetamine; popularly known as ecstasy) to suicidal
behaviors among youth.
MDMA is an indirect serotonergic agonist which causes flooding of the serotonin system,
usually leading to temporary positive changes in mood. Clinical research has found that, in
young adults, MDMA’s metabolites may remain detectable in blood plasma up to 146 hours
(about six days) after ingestion of a high dose, while a low dose will become undetectable
after 47 hours (i.e., about two days) (Kolbrich et al., 2008). Aftereffects associated with
ecstasy use include lethargy, anorexia, decreased motivation, sleepiness, depression, and
fatigue. (Ajaelo et al., 1998; Gabbard, 2001; Holmes et al., 1999; Hoshi et al., 2006; Huxster
et al., 2006; Travers and Lyvers, 2005). Youth ecstasy use typically takes place on weekends
at rave-style parties (Bahora et al., 2009; Hopfer et al., 2006; Hopper et al., 2006), and
‘Suicide Tuesday’ is a term that is sometimes used to describe the negative aftereffects that
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users may experience following an episode of ecstasy use (Bahora et al., 2009). With regular
use, ecstasy may damage serotonin neurons, causing a decrease in serotonin production
(Karlsen et al., 2008). Serotonin deprivation resulting from this process may lead to
increases in depressive symptoms, impulsivity (Butler and Montgomery, 2004), aggression
(Milani et al., 2005) and poor judgment (Morgan et al., 2006). Some of these changes may
not be reversible even with prolonged abstinence (Morgan et al., 2002).
Few studies have examined the relationship between ecstasy use and suicidality in detail.
One 10-year clinical retrospective study did examine the relationship between suicidality
and ecstasy use among 178 adolescent psychiatric inpatients (Shoval et al., 2006), and found
ecstasy use to be significantly associated with subsequent suicide attempt. Studies using
large-scale epidemiological survey data to examine this relationship are called for. The
current study, which focuses on the relationship between ecstasy use and suicidal behavior,
and is based on a nationally representative sample of U.S. adolescents ages 12 to 17, will
help to fill this research gap.
A study that aims to test whether ecstasy use independently contributes to suicidal behaviors
should take potentially shared risk factors, such as socio-demographic, parental/family, and
individual-level factors, into account. Previous studies have found that Asian or White race/
ethnicity (Bae et al., 2005) and female gender (Roy and Janal, 2006; Weissman et al., 1999)
are associated with youth suicide attempt. Parental/familial and individual factors that have
been found to be associated with adolescent suicidal behaviors include residential instability
(Brent et al., 1994), being from a single parent family (Wichstrom, 2000), not feeling able to
discuss serious problems with one’s parents (Borowsky et al., 2001), and having conduct
disorder (Darke et al., 2003) or an anxiety disorder (Sareen et al., 2005). Many of these
factors have also been found to be related to use of ecstasy (Huizink et al., 2006; Lieb et al.,
2002; Martins and Alexandre, 2009; Martins et al., 2007; Yacoubian, 2003; Zimmermann et
al., 2005).
Using data from a nationally representative sample of adolescents, this study examines (1)
the relationship of ecstasy use with suicidal ideation and attempt among adolescents ages
12–17; and (2) whether the observed association can be explained by those socio-
demographic, parental/family, and individual-level factors that are associated with both
ecstasy use and suicidality. The findings from this study will help improve understanding of
the relationship between use of ecstasy and suicidal behavior. The clinical and public health
implications of the findings are also explored.
2. METHODS
2.1. Sample and Data
The adolescent (ages 12–17) subsample (N=19,430) of the 2000 National Household Survey
on Drug Abuse (NHSDA) was selected for use in our analyses. The target population for the
2000 NHSDA is defined as the civilian, non-institutionalized population of the United States
who are 12 years of age and older (SAMHSA, 2001). The weighted adolescent subsample is
a representative sample of non-institutionalized adolescents ages 12–17 in the United States.
Within this adolescent subsample, a small number of respondents (N=129) did not provide
information on suicidal behaviors, and, therefore, were not included in our analyses. Thus,
the actual sample size for the current study was 19,301.
Trained interviewers interviewed respondents in their homes in person, using a computer-
assisted personal interview. Survey sections focusing on substance use and other sensitive
topics were administered using an audio computer-assisted self-interview, in order to
provide the respondent with a highly private and confidential means of responding to
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questions and to increase the level of honest reporting. Weighted response rates for
household screening and for interviewing were 92.8% and 73.9%, respectively. Further
details on the study’s sampling design, study procedures are available elsewhere (SAMHSA,
2001).
This study’s secondary data analyses were conducted in full compliance with the
Institutional Review Board of the New York State Psychiatric Institute.
2.2. Measures
2.2.1. Suicidal Behaviors—The suicidal behavior outcome variable had three categories,
all referring to behaviors in the past year: no suicidal behaviors; ideation only; and suicide
attempt. Suicidal ideation was defined as responding affirmatively to the question: “During
the past 12 months, has there been a time when you thought seriously about killing yourself?
Suicide attempt was defined as a positive response to the question: “In the past 12 months,
have you tried to kill yourself?”
2.2.2. Ecstasy and Other Drug use—Adolescents were asked about their lifetime use
of ecstasy, and of other drugs including marijuana, cocaine, crack, inhalants, hallucinogens,
heroin, stimulants, sedatives, tranquilizers, analgesics and any psychotherapeutic drugs used
nonmedically.
A three-category drug use variable was created by combining information from the lifetime
ecstasy use variable with information from the drug use summary variable provided in the
dataset, “Any illicit drug – ever used”. The created three-category variable was used to
divide the adolescents into three groups for the purposes of the analyses: (1) No illicit drug
use, (2) Used other drugs only, and (3) Used ecstasy.
2.2.3. Socio-Demographic Factors—Demographic measures such as respondent age,
gender, and race/ethnicity were included in the NHSDA interview. The main race/ethnicity
variable had four categories: Non-Hispanic White, African American, Hispanic, and
“Other.” The annual household income levels of the adolescents’ families were classified
into the following four categories based on adolescents’ estimates: $0–19,999, $20,000–
$39,999, $40,000–$74,999, and $75,000 or above.
2.2.4. Family, Parental, and Individual Factors
Residential instability: This was defined as having moved three or more times in the past
five years.
Child not living with both parents: This was based on youths’ reports regarding family
structure.
Able to talk with parents about serious problems: Respondents disagreeing with the
statement “There is no one I can talk to about serious problems”, and reporting that they
could talk to their mother, father, or guardian about such problems, were coded affirmatively
on this measure.
Psychopathology: Measures of psychopathology, including anxiety disorders, and conduct
disorder, were adapted from the Diagnostic Interview Schedule for Children (DISC)
Predictive Scales (DPS 4) (Lucas et al., 2001) (a screening measure derived from the
National Institute of Mental Health’s DISC Version IV)(Shaffer et al., 2000). The DPS
instrument includes only those DISC items that are most highly predictive of DSM-IV
(American Psychiatric Association, 1994) diagnoses. The recall period used for all of the
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psychopathology symptom items was the past year. Psychometric data on the DPS are
reported elsewhere (Lucas et al., 2001). The DPS items were used to detect
psychopathological symptom clusters. A symptom cluster is a group of symptoms derived
from the DSM-IV criteria for a particular disorder, not including criteria related to
impairment or symptom duration. The cutoff points used for the symptom clusters were
selected based on previous methodological research (Chen et al., 2005).
The number of positive anxiety symptom clusters found, including: social phobia, separation
anxiety disorder, agoraphobia, panic disorder, generalized anxiety disorder, specific phobia,
and obsessive compulsive disorder, was used in the analyses as a measure of level of anxiety
problems. For conduct problems, a dichotomous measure indicating the presence of the
conduct disorder symptom cluster was used.
2.3. Data Analysis
Initially, bivariate analyses were used to assess the associations between the suicidal
behavior categories and use of ecstasy and other drugs. Then the associations between the
suicidal behaviors and the other individual- and family-level risk factors were examined. To
detect group differences, chi-square tests were used for categorical variables, while the
ANOVA procedure was used for continuous variables. Bonferroni correction was used to
adjust the significance levels, alpha = 0.05/3 = 0.017, for multiple pair-wise comparisons
between suicidal behavior groups. All tests were two-tailed. Similar analyses were
conducted to examine the relationships between the three-category drug use variable and
each of the remaining risk factors.
Multinomial logistic regression analysis was then applied to the three-category suicidal
behavior outcome variable. The regression analyses were conducted hierarchically in two
steps. In step one, in addition to our main predictor of interest, i.e., ecstasy and other drug
use, the major socio-demographic factors were included in the model. In the second step,
those other variables that had been found, in the bivariate analyses, to be significantly
associated with both suicidal behavior and ecstasy use were added in. All analyses were
weighted and were conducted using SUDAAN Version 8.0 (Research Triangle Institute,
2001), to take into account the complex sampling design of the national survey data.
3. RESULTS
Among the 19,301 adolescents, 48% were girls, 66% were Whites, 14% were African
Americans and 14% were Hispanics. About one third were 12–13 years old, one third were
14–15, and the remaining third were 16–17 years old. In terms of suicidal behaviors, about
4.6% of the sample reported having attempted suicide in the year prior to the interview,
while about 8.1% reported suicidal ideation only. About 2.6% had ever used ecstasy, while
24.3% had used only drugs other than ecstasy.
3.1. Bivariate Analysis
Table 1 shows the results of the bivariate analyses of the relationships between suicidal
behaviors and ecstasy use, and between suicidal behaviors and the other risk factors. The
ecstasy and other drug use variable was found to be significantly associated with the suicidal
behavior variable. Among adolescents who had used ecstasy, more than 19% had attempted
suicide in the year prior to the interview. This rate of suicide attempt was almost twice as
high as that of the adolescents who had used other drugs only and nine times that of the non-
drug users. With regard to the proportions having suicidal ideation alone, on the other hand,
the ecstasy users were very similar to those with other drug use only, with these two groups’
rates of suicidal ideation being about double that of the non-drug users.
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The results of the bivariate analyses of the associations between suicidal behaviors and other
possible risk factors indicate that suicidal behaviors are associated with older age, female
gender, the “other” racial/ethnic category, low family income, residential instability, not
living with both parents, and feeling unable to talk with one’s parents about serious
problems. Also, adolescents with anxiety and/or conduct problems were more likely to
report suicidal behaviors. A similar set of analyses was conducted to examine ecstasy and
other drug use in relation to the same set of risk factors. Except for gender, all of these risk
factors were found to be significantly associated with the ecstasy and other drug use variable
(results not shown).
3.2. Multinomial Logistic Regression
The results of the multinomial logistic regression analyses are shown in Table 2. As
expected, the associations between the drug use categories and suicide attempt emerged as
much stronger than those with suicidal ideation alone. The Model 1 results indicate that the
association between suicidal ideation and other drug use only is essentially identical to that
between suicidal ideation and ecstasy use (the Adjusted Odds Ratios (AORs) are 2.9 and 2.8
respectively); however, the magnitude of the association between suicide attempt and
ecstasy use is strikingly higher than that between suicide attempt and other drug use only
(with AORs of 13.2 and 6.2, respectively). In other words, while adolescents using only
drugs other than ecstasy were about 6 times as likely to attempt suicide as non-drug users,
adolescents using ecstasy were about 13 times as likely to attempt suicide compared to the
non-drug users. Table 2 also shows that in Model 2, after the other family and individual
factors were controlled for, the associations between the drug use categories and the suicidal
behaviors remained significant, but were somewhat reduced in magnitude, indicating that
the relationship between the two variables can be partially explained by these factors.
However, the relationship between suicide attempt and ecstasy use remained stronger than
that between suicide attempt and other drug use only (with AORs of 5.5 and 3.5
respectively). This difference was statistically significant at p = .0121. Among the other risk
factors, being 14–15 years old, being female, not feeling able to talk to one’s parents about
serious problems, anxiety problems, and conduct problems, were all found to significantly
contribute to the likelihoods both of suicidal ideation alone, and of suicide attempt.
Residential instability, on the other hand, was found to contribute only to suicide attempt.
4. DISCUSSION
This study examined the relationship between ecstasy use and suicidal behaviors. One
strength of this study is its use of data from a nationally representative sample of
community-dwelling youth. Another strength is that it controlled for the impact of
demographic, family, and individual factors that are associated both with ecstasy use and
with suicidality, in examining the impact of ecstasy use on suicidal behaviors, and compared
the impact of ecstasy use with that of use of other illicit drugs only.
The results of the study indicate that ecstasy use is strongly associated with suicide attempt.
Rates of suicide attempt were found to be considerably higher among adolescents with a
history of ecstasy use than among either non-drug users, or users of other drugs only. This
finding held even after controlling for the impact of factors such as age, gender, parent-child
communication, and anxiety and conduct problems.
There are several possible explanations for the observed association between ecstasy use and
suicide attempt. With regard to the effects of ecstasy use on behavior, the drop in serotonin
levels that tends to occur a few days after an episode of ecstasy use, with its attendant
increase in depressive symptoms, may temporarily increase users’ vulnerability to suicidal
behaviors. With continued, regular use of ecstasy, users’ general vulnerability to depressive
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symptoms may also increase (Keyes et al., 2008), thus increasing their overall risk for
suicidal behavior. Impulsivity, too, may increase as a result of ecstasy use (Butler and
Montgomery, 2004; Morgan et al., 2006; Wan et al., 2009), thus increasing the risk that an
individual will act on suicidal thoughts (Carballo et al., 2006; Zalsman et al., 2008). Studies
have also found, however, that prior to initiating ecstasy use, many users already have a
history of depression or behavioral problems (Falck et al., 2006; Guillot, 2007; Lieb et al.,
2002; Martins et al., 2006), or a genetic predisposition to psychiatric illness (Karlsen et al.,
2008). Further, more targeted, research is needed to test specific pathways.
4.1. Limitations
The study dataset was a cross-sectional one, meaning that we could not ascertain whether
the subjects’ suicide attempts preceded or followed their first use of ecstasy. No causal
inferences can be made on the basis of our results. Also, it has been observed that ecstasy
users tend to be especially heavy users of drugs in general (Keyes et al., 2008). Thus, the
observed association between ecstasy use and suicide attempt may be an indirect one, where
other specific drugs play an important role. Although this study’s analyses did divide the
sample into three groups with regard to drug use - non-drug users, users of other illicit drugs
only, and ecstasy users - it was not possible to fully control for the effects of use of other
specific drugs in the analyses. Our results do, nevertheless, indicate that ecstasy-using
adolescents may require enhanced suicide prevention and intervention efforts.
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Table 1
Suicidal Behaviors, Ecstasy and Other Drug Use, and Other Related Factors (N=19,301)
FACTORS
Suicidal Behaviors
p valueaNone (N=16,857) Ideation Only (N=1,567) Attempt (N=877)
Drug use
 No illicit drug use 91.88 5.98 2.14 <0.0001
 Used other drugs only 75.83 13.83 10.35
 Used Ecstasy 68.61 12.02 19.37
Age (%)
 12 – 13 90.31 6.65 3.04 <0.0001
 14 – 15 86.00 8.67 5.33
 16 – 17 85.89 8.79 5.32
Gender (%)
 Girls 83.52 9.91 6.57 <0.0001
 Boys 91.08 6.26 2.67
Ethnicity (%)
 White 87.54 7.89 4.58 0.0098
 African-American 88.07 8.48 3.45
 Hispanic 87.43 7.26 5.3
 Other 83.98 10.54 5.48
Household Income (%)
 Under $20,000 85.95 8.58 5.47 0.0085
 $20,000–39,999 86.83 8.03 5.13
 $40,000–74,999 87.83 7.80 4.36
 $75,000 or More 88.48 7.99 3.53
Residential Instability (%)
 No 88.24 7.73 4.03 <0.0001
 Yes 82.01 10.01 7.98
Living with Both Parents (%)
 No 84.88 9.15 5.97 <0.0001
 Yes 88.34 7.63 4.03
Able to talk with parents about serious problems (%)
 No 78.25 13.11 8.64 <0.0001
 Yes 92.02 5.47 2.51
Probable Anxiety Disorders (Mean) 0.66 1.73 2.24 <0.0001
Conduct Problems (%)
 No 90.33 6.57 3.11 <0.0001
 Yes 64.85 19.42 15.73
a
p-values are from chi-square tests for categorical variables; from ANOVA for continuous variables.
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Table 2
Results of Multinomial logistic regression analyses predicting suicidal behaviors
PREDICTORS
MODEL 1 MODEL 2
Suicidal Ideation Suicide Attempt Suicidal Ideation Suicide Attempt
AOR(95%CI)a AOR(95%CI) AOR(95%CI) AOR(95%CI)
Drug Use
 No illicit drug use 1.0 1.0 1.0 1.0
 Used other drugs only 2.9*** (2.5, 3.3) 6.2*** (5.2, 7.5) 1.9*** (1.6, 2.2) 3.5*** b (2.8, 4.3)
 Used Ecstasy 2.8*** (2.0, 3.8) 13.2*** (9.5, 18.3) 1.5* (1.0, 2.1) 5.5*** b (3.8, 8.1)
Age
 12–13 1.0 1.0 1.0 1.0
 14–15 1.2 (1.0, 1.3) 1.3* (1.0, 1.6) 1.2* (1.1, 1.5) 1.4** (1.1, 1.9)
 16–17 1.0 (0.8, 1.2) 0.9 (0.7, 1.1) 1.2 (1.0, 1.4) 1.2 (0.9, 1.6)
Gender
 Boys 1.0 1.0 1.0 1.0
 Girls 1.8*** (1.6, 2.0) 2.9*** (2.4, 3.5) 1.5*** (1.4, 1.8) 2.3*** (1.9, 2.8)
Ethnicity
 White 1.0 1.0 1.0 1.0
 African-American 1.1 (0.9, 1.3) 0.8 (0.6, 1.0) 0.9 (0.7, 1.1) 0.5*** (0.4, 0.7)
 Hispanic 0.9 (0.8, 1.1) 1.1 (0.9, 1.4) 0.9 (0.7, 1.1) 1.1 (0.8, 1.4)
 Other 1.4* (1.1, 1.9) 1.2 (0.8, 1.9) 1.3 (1.0, 1.7) 1.1 (0.7, 1.7)
Household Income
 Under $20,000 1.0 1.0 1.0 1.0
 $20,000–39,999 0.9 (0.8, 1.1) 0.9 (0.7, 1.2) 1.0 (0.8, 1.2) 1.0 (0.8, 1.3)
 $40,000–74,999 0.9 (0.8, 1.1) 0.8 (0.6, 1.0) 1.1 (0.9, 1.4) 1.0 (0.8, 1.3)
 $75,000 or More 1.0 (0.8, 1.2) 0.7** (0.5, 0.9) 1.1 (0.9, 1.5) 0.9 (0.7, 1.2)
Residential Instability
 No 1.0 1.0
 Yes 1.0 (0.9, 1.2) 1.3* (1.0, 1.7)
Living with Both Parents
 No 1.1 (0.9, 1.2) 1.2 (0.9, 1.4)
 Yes 1.0 1.0
Able to talk with parents about serious problems
 No 2.1*** (1.9, 2.4) 2.5*** (2.0, 3.0)
 Yes 1.0 1.0
Anxiety Problems (mean) 1.5*** (1.5, 1.6) 1.7*** (1.6, 1.8)
Conduct Problems
 No 1.0 1.0
 Yes 2.4*** (2.0, 2.8) 2.9*** (2.3, 3.5)
*
p ≤.05;



















Adjusted odds ratio. 95% confidence interval for odds ratio.
b
The difference between the other drugs only group and the ecstasy use group, with regard to suicide attempt, was statistically significant at p=.
0121.
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